SB 220025

SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM) . SB 220025 also inhibits p56Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation[1][2].

Product Specifications

CAS Number

[165806-53-1]

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H335

Target

P38 MAPK; PKC; Src

Type

Reference compound

Related Pathways

Epigenetics; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sb-220025.html

Purity

99.90

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCNCC4)=N1

Molecular Formula

C18H19FN6

Molecular Weight

338.38

Precautions

H301, H315, H319, H335

References & Citations

[1]Tomizawa A, et al. Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci. 2009 Sep 9;85 (11-12) :457-61.|[2]Jackson JR, et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther. 1998 Feb;284 (2) :687-92.